BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today ...
Add Yahoo as a preferred source to see more of our stories on Google. MetaVia's DA-1726 is a dual OXM analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP-1RA) and glucagon ...
GOTHENBURG, NE / ACCESS Newswire / December 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for ...
Hi, everyone, and thank you for joining us today. I'm Michelle Corral, Vice President of Corporate Communications and Investor Relations at Tenaya. Today, we are excited to present initial data from ...
Neurodegeneration specialist Vesper Bio ApS has announced positive results from the phase Ib/II trial of its oral sortilin inhibitor VES-001 in frontotemporal dementia. The small study involved six ...
Add Yahoo as a preferred source to see more of our stories on Google. French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...
Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II ...
BASEL, Switzerland – 29 April 2025 – Nouscom, a clinical-stage biotech company developing next-generation neoantigen-targeted off-the-shelf and personalized cancer immunotherapies, today announced ...
(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 oral ...
Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial ...
Morgan Stanley’s MS fourth-quarter 2024 earnings of $2.22 per share handily outpaced the Zacks Consensus Estimate of $1.65. The bottom line also rose substantially from 85 cents in the prior-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results